CA2782075C - Nestorone/estradiol transdermal gel - Google Patents

Nestorone/estradiol transdermal gel Download PDF

Info

Publication number
CA2782075C
CA2782075C CA2782075A CA2782075A CA2782075C CA 2782075 C CA2782075 C CA 2782075C CA 2782075 A CA2782075 A CA 2782075A CA 2782075 A CA2782075 A CA 2782075A CA 2782075 C CA2782075 C CA 2782075C
Authority
CA
Canada
Prior art keywords
estradiol
transdermal
progestin
female
nes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2782075A
Other languages
English (en)
French (fr)
Other versions
CA2782075A1 (en
Inventor
Regine Sitruk-Ware
Dario Norberto Ramon Carrara
Arnaud Grenier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Population Council
Original Assignee
Antares Pharma IPL AG
Population Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antares Pharma IPL AG, Population Council filed Critical Antares Pharma IPL AG
Publication of CA2782075A1 publication Critical patent/CA2782075A1/en
Application granted granted Critical
Publication of CA2782075C publication Critical patent/CA2782075C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2782075A 2009-12-17 2010-12-17 Nestorone/estradiol transdermal gel Active CA2782075C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28751409P 2009-12-17 2009-12-17
US61/287,514 2009-12-17
PCT/US2010/060941 WO2011084668A1 (en) 2009-12-17 2010-12-17 Nestorone®/estradiol transdermal gel

Publications (2)

Publication Number Publication Date
CA2782075A1 CA2782075A1 (en) 2011-07-14
CA2782075C true CA2782075C (en) 2015-06-30

Family

ID=43640394

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2782075A Active CA2782075C (en) 2009-12-17 2010-12-17 Nestorone/estradiol transdermal gel

Country Status (14)

Country Link
US (1) US9682087B2 (enExample)
EP (1) EP2512486B1 (enExample)
JP (1) JP6082249B2 (enExample)
KR (2) KR101928321B1 (enExample)
CN (1) CN102753180A (enExample)
AU (1) AU2010339867B2 (enExample)
BR (1) BR112012014059B1 (enExample)
CA (1) CA2782075C (enExample)
ES (1) ES2641613T3 (enExample)
IN (1) IN2012DN04867A (enExample)
MX (1) MX363536B (enExample)
NZ (1) NZ600907A (enExample)
WO (1) WO2011084668A1 (enExample)
ZA (1) ZA201204267B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
CN102657661A (zh) * 2012-04-15 2012-09-12 温州医学院 Nestorone在制备治疗阿尔茨海默病的药物用途
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
RU2648470C2 (ru) * 2016-03-03 2018-03-26 Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральский государственный медицинский университет Министерства здравоохранения Российской Федерации" (ГБОУ ВПО УГМУ Минздрава России) Способ оптимизации лечения женщин кардиотропной терапией и заместительной гормональной терапией при эстрогенодефиците с артериальной гипертензией в позднем репродуктивном периоде
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
EP4313318A4 (en) * 2021-03-30 2025-03-26 Viatris Inc. LOW-DOSE ESTROGEN TRANSDERMAL SYSTEMS AND METHODS OF PRODUCTION AND USE THEREOF

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2180690T3 (es) 1990-06-01 2003-02-16 Population Council Inc Preparacion de composiciones que comprenden st1435 para aplicacion topica.
US5198223A (en) 1990-10-29 1993-03-30 Alza Corporation Transdermal formulations, methods and devices
US5122382A (en) * 1990-10-29 1992-06-16 Alza Corporation Transdermal contraceptive formulations, methods and devices
JPH04342531A (ja) 1991-05-21 1992-11-30 Sekisui Chem Co Ltd 経皮吸収製剤
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
BR112012009306A2 (pt) 2009-10-19 2016-06-07 Population Coucil Inc método para regeneração de mielina em um paciente

Also Published As

Publication number Publication date
ES2641613T3 (es) 2017-11-10
WO2011084668A1 (en) 2011-07-14
CA2782075A1 (en) 2011-07-14
EP2512486A1 (en) 2012-10-24
EP2512486B1 (en) 2017-06-28
US20130045953A1 (en) 2013-02-21
IN2012DN04867A (enExample) 2015-09-25
KR20120107492A (ko) 2012-10-02
JP6082249B2 (ja) 2017-02-15
BR112012014059A8 (pt) 2017-12-26
AU2010339867B2 (en) 2014-07-24
JP2013514984A (ja) 2013-05-02
CN102753180A (zh) 2012-10-24
AU2010339867A1 (en) 2012-07-19
BR112012014059A2 (pt) 2016-07-05
BR112012014059B1 (pt) 2020-03-10
ZA201204267B (en) 2013-01-31
KR20180084149A (ko) 2018-07-24
KR101928321B1 (ko) 2018-12-12
NZ600907A (en) 2013-11-29
MX2012006755A (es) 2012-11-23
MX363536B (es) 2019-03-27
US9682087B2 (en) 2017-06-20

Similar Documents

Publication Publication Date Title
US9682087B2 (en) Nestorone®/estradiol transdermal gel
JP5441966B2 (ja) 活性薬の経皮又は経粘膜適用のための使用及び製剤
US8647665B2 (en) Methods of treating hot flashes with formulations for transdermal or transmucosal application
US6306914B1 (en) Progestin therapy for maintaining amenorrhea
JP2013514984A5 (enExample)
Sitruk-Ware et al. Patent: Nestorone®/estradiol transdermal gel
JP2025516643A (ja) プロゲスチン／テストステロン経皮ゲル剤
CN1997357A (zh) 透皮或透粘膜应用活性剂的用途和制剂
Cronje et al. Vaginal estrogens: is there a role for their use?
HK1108632A (en) Uses and formulations for transdermal or transmucosal application of active agents
MX2008013207A (es) Metodos para tratamiento de bochornos con formulaciones para aplicacion transdermica o transmucosa.
HK1132453A (en) Methods of treating hot flashes with formulations for transdermal or transmucosal application

Legal Events

Date Code Title Description
EEER Examination request
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251020

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260128

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260203

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260801